Jung Hwan Lee, PhD

CEO at Interoligo Corp.

Speaker

As a chemistry major, I did research on antibiotics at the graduate school (Master's, Doctoral) in chemistry department at Seoul National University. In 1995, I joined Samsung General Chemical and the pharmaceutical research team, developed and commercialized chiral drugs such as antibiotics and their intermediates. After joining Samchully Pharm.(Now ST Pharm) in 1998, I worked as a team leader at the head of the drug development office/New API team, jointly researching the development of antiviral drugs (HIV, HBV, etc.) and clinical New API development jointly with global drug discovery companies. In 2001, in Professor David S Lawrence(Now Chair, Division of Chemical Biology & Medicinal Chemistry, University of North Carolina at Chapel Hill)’s Lab at Albert Einstein College of Medicine in New York, I developed PKCa selective peptide inhibitor with the highest efficacy and selectivity using Combinatorial Chemistry and High throughput Synthesis/Screening Tech, which is the most powerful protein binding-site-directed inhibitor ever reported for a protein kinase. In 2006, at POSTECH (Pohang University of Science and Technology), I established an aptamer platform and discovered new aptamers for over 250 new targets. Research areas were aptamer-based diagnosis, imaging (PET/CT and MRI contrast agents), and therapeutic agent. In 2015, Interoligo Co., Ltd. was established based on aptamer platform technology for caner target therapy.